CLAIMS

5

- 1. An adhesive composition which lacks functional groups containing reactive hydrogen moieties and contains no post-polymerization chemical crosslinker comprising, on a dry weight basis, from about 50 to about 98% of an alkyl acrylate monomer and/or alkyl methacrylate monomer and from about 2 to about 50% of a polymerizable non-cyclic nitrogen-containing monomer.
- The adhesive of claim 1 wherein the polymerizable nitrogen
 containing monomer is selected from the group consisting of an N-substituted acrylamide monomer, an N-substituted methacrylamide monomer, vinylacetamides, nitriles, or mixtures thereof.
- 3. The adhesive of claim 2 wherein the nitrile is methacrylonitrile or 2-cyanoethylacrylate.
 - 4. The adhesive of claim 1 which has a Tg of less than about 10°C
- 5. The adhesive of claim 4 wherein the alkyl acrylate monomer is 2-ethylhexyl acrylate and/or n-butyl acrylate.
- 6. The adhesive of claim 5 wherein the nitrogen-containing monomer is an N-substituted acrylamide monomer and/or an N-substituted methacrylamide monomer.

- 7. The adhesive of claim 6 wherein the nitrogen-containing acrylamide is t-octyl acrylamide.
- 8. The adhesive of claim 1 further comprising a therapeutic 5 agent.
 - 9. The adhesive of claim 8 wherein the therapeutic agent is a pharmacologically active agent.
- 10. A transdermal drug delivery system comprising the adhesive of claim 8.
 - 11. The transdermal drug delivery system of claim 10 wherein the adhesive serves as a carrier for the therapeutic agent.

12. The transdermal drug delivery system of claim 10 comprising an adhesive layer, and a backing layer.

- 13. The transdermal drug delivery system of claim 12 further20 comprising a release layer.
 - 14. A method of administering a therapeutic agent to a patient comprising applying to a body surface of a patient a transdermal drug delivery system comprising the adhesive of claim 1 and a therapeutic agent.

25

CHARACTER STREET

15